ArticleMolecular cancer2025
Targeting the CD47-HCK-LGALS9 axis disrupts proliferation-immunosuppression coupling in early-stage endometrial cancer.
Article in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Silica based nanocarriers for combination immunotherapy targeting the tumor immune microenvironment.Drug delivery and translational research · 2026Review
- TMEM184A promotes progression and drug resistance in colorectal cancer: a bioinformatics and clinical study.Scientific reports · 2026Article
- AI-driven drug-target interaction prediction: current progress, challenges, and future roadmap for precision medicine.Journal of computer-aided molecular design · 2026Review
- Macrophage polarization in gynecologic malignancies: key signaling pathways and clinical perspectives.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundsSignificant heterogeneity was observed in the epithelial-derived endometrial cancer (EC), which contributes to different prognostic outcomes. While the mechanisms involved in this heterogeneity in the tumor microenvironment (TME) of early-stage EC remain poorly defined.
methodsSingle-cell RNA sequencing, spatial transcriptomics, and multiplex immunofluorescence (mIF) were applied to characterize cellular subpopulations in early-stage EC. EC cell proliferation was assessed by CCK-8 and flow cytometry (FC). Furthermore, the epithelial dynamics and macrophage interactions were also investigated in vitro by molecular docking and GST pull-down mass spectrometry. Phagocytic activity was also evaluated by FC and immunofluorescence. Moreover, the upstream transcription factors were identified using CUT&Tag. For in vivo study, an organoid–macrophage co-culture model was established to mimic the EC microenvironment, and altered organoid proliferation and macrophage phagocytosis were confirmed. CD47 was evaluated as a potential prognostic marker by proteomic analysis and immunohistochemistry.
resultsWe identified a previously unrecognized epithelial subpopulation (CD47⁺CDK1⁺) that was strongly linked to cell-cycle signaling and malignant proliferation. This subpopulation interacts closely with macrophages through the CD47–Galectin 9 (LGALS9) receptor-ligand pair. Functionally, CD47 inhibition suppressed EC cell proliferation and induced apoptosis, while CD47 overexpression enhanced the proliferative capacity of EC patient-derived organoids (PDOs). EC cells and PDOs engaged macrophages through the CD47–HCK (Hemopoietic Cell Kinase) axis, driving the secretion of immunosuppressive molecules LGALS9, IL-10, and TGF-β1 and forming an immunosuppressive TME. In turn, macrophage-derived LGALS9 reinforced EC cell and PDO proliferation via CD47, establishing a positive feedback loop involving CD47–HCK–LGALS9. Furthermore, estrogen-related receptor gamma (ERRγ) was identified as an upstream transcriptional regulator of CD47, and its expression was suppressed by progesterone.
conclusionsRegulated by ERRγ, an optimistic therapeutic target, the CD47-HCK-LGALS9 axis modulated cellular proliferation-immunosuppression coupling in early-stage EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.